Prelude Capital Management’s MGC Diagnostics Corporation MGCD Stock Holding History

Prelude Capital Management’s Portfolio MGCD Stock Details MGCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4,214	Closed	-$46K	–	1903
2017 Q4	$46K	Buy	4,214 +2,500	+146%	+$24.1K	﹤0.01%	955
2017 Q3	$15K	Hold	1,714	–	–	﹤0.01%	1375
2017 Q2	$14K	Buy	1,714 +349	+26%	+$2.87K	﹤0.01%	1344
2017 Q1	$11K	Buy	+1,365	New	+$12K	﹤0.01%	1355
2015 Q4	–	Sell	-3,054	Closed	-$20K	–	1840
2015 Q3	$20K	Hold	3,054	–	–	﹤0.01%	1253
2015 Q2	$17K	Buy	3,054 +500	+20%	+$3.11K	﹤0.01%	1471
2015 Q1	$19K	Buy	+2,554	New	+$17.8K	﹤0.01%	1761
2014 Q2	–	Sell	-2,000	Closed	-$23K	–	2311
2014 Q1	$23K	Buy	+2,000	New	+$22.6K	﹤0.01%	1652

Prelude Capital Management's MGCD Position: Q1 2018 in Review

Prelude Capital Management sold out of MGC Diagnostics Corporation (MGCD) in Q1 2018, closing a stake of 4,214 shares — an estimated $46K sold.

Prelude Capital Management first reported a position in MGCD in Q1 2014 and held it in 8 quarters. The position peaked at $46K in Q4 2017. 0 funds tracked by Wall St. Rank hold MGCD as of Q1 2018.

Prelude Capital Management reported no remaining MGC Diagnostics Corporation position as of Q1 2018 after selling out during the quarter.
Prelude Capital Management sold 4,214 MGC Diagnostics Corporation shares in Q1 2018, an estimated $46K.
Prelude Capital Management first reported a position in MGC Diagnostics Corporation in Q1 2014 and held it in 8 quarters.
Prelude Capital Management's MGC Diagnostics Corporation position peaked at $46K in Q4 2017.
0 funds tracked by Wall St. Rank held MGC Diagnostics Corporation as of Q1 2018.

Based on Prelude Capital Management's 13F filing for Q1 2018, filed 15 May 2018.